PT-141 (10 mg) + Melanotan II (10 mg) Stack

Research overview by Biohacking Elite · Last updated October 24, 2026
Research information notice

This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.

PEPTIDE STACKS

PT-141 (10 mg) + Melanotan II (10 mg) Stack

RESEARCH & EDUCATIONAL REFERENCE GUIDE

This information is for research and educational use only.

! For research and educational purposes only. Review all research information, limitations and references before interpretation.
NEUTRAL LABORATORY CALCULATIONS Use the Research Calculator for concentration, dilution and unit-conversion math. It does not provide or recommend a personal dose or administration schedule.
PT-141 (10 mg) + Melanotan II (10 mg) Stack
01

Quick Reference

Alternate / Common Names
Bremelanotide + Melanotan II PT-141 / Melanotan II stack
Classification
Multi-vial melanocortin receptor agonist research stack
Vial / Reference Strength
PT-141 10 mg + Melanotan II 10 mg (separate vials)
Product / Research Format
Two separate lyophilized peptide vials used as a research stack

What is PT-141 (10 mg) + Melanotan II (10 mg) Stack?

Research overview based on the cited scientific literature.

• Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).

Storage Instructions

Proper storage preserves peptide quality.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; PT-141 shows short-term room-temperature stability (~3 weeks) if needed[7].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 1 week for optimal potency.
• Avoid repeated freeze–thaw cycles; allow vials to reach room temperature before opening to reduce condensation.

How is PT-141 (10 mg) + Melanotan II (10 mg) Stack studied?

PT-141 and Melanotan II are both synthetic cyclic peptide analogues that act on melanocortin receptors, particularly MC3R and MC4R in the central nervous system[2][5]. PT-141 (bremelanotide) is a metabolite of Melanotan II and was developed specifically for its effects on sexual function without significant pigmentation activity. It is FDA-approved for hypoactive sexual desire disorder in premenopausal women[1][3]. Melanotan II retains both melanogenic and sexual-function properties, stimulating melanin production in skin cells while also activating central pathways involved in sexual arousal[5][6].

What does the research report about PT-141 (10 mg) + Melanotan II (10 mg) Stack?

Observations from clinical and research literature.
PT-141
• Shown to increase sexual desire and reduce distress associated with low libido in clinical trials[2][3].
• Common side effects include nausea, flushing, headache, and injection-site reactions[4].
• May cause transient increases in blood pressure; use with caution in those with cardiovascular conditions[1].
Melanotan II
• Studied for inducing skin pigmentation and for effects on erectile function[5][6].
• Common side effects include nausea, facial flushing, fatigue, and appetite suppression, particularly during initial dosing[6].
• May cause darkening of existing moles or nevi; monitoring is advised.

Important Note

This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.

What are the limitations of the research on PT-141 (10 mg) + Melanotan II (10 mg) Stack?

Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.

References

[1]
FDA — Bremelanotide (Vyleesi) prescribing information: dosing, safety, and use limitations
FDA
[2]
NCBI Bookshelf (LiverTox) — Bremelanotide: mechanism, clinical use, and hepatic safety profile
NCBI Bookshelf
[3]
PMC — Bremelanotide for treatment of female hypoactive sexual desire disorder: clinical trial review
PMC
[4]
Mayo Clinic — Bremelanotide (subcutaneous route): side effects, dosage, and precautions
Mayo Clinic
[5]
PubMed — Evaluation of Melanotan-II: pilot phase-I clinical study on safety and efficacy
PubMed
[6]
RxList — Melanotan-II: uses, side effects, dosing, and precautions overview
RxList
[7]
Bachem — Handling and storage guidelines for peptides: lyophilized and reconstituted stability
Bachem

Additional Research and Background

[1]
PMC — Subcutaneous drug injection: pharmacologic considerations and clinical review
PMC

Related research and educational resources

Scroll to Top